Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-04T00:44:54.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision advances from v3.7.1 to v3.7.2. The study page continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-21T00:47:35.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-07T00:53:06.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page shows a 403 Forbidden error instead of the study record details, blocking access to the study content. This indicates the study information is not currently accessible on the page.
    Difference
    17%
    Check dated 2026-09-23T00:59:49.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.6 to v3.7.0 on the page, indicating a version update rather than a change to the study details or eligibility information.
    Difference
    0.1%
    Check dated 2026-09-16T00:15:40.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Revision indicator on the page was updated to v3.6.6, replacing the previous v3.6.5.
    Difference
    0.1%
    Check dated 2026-09-01T19:32:36.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.